Pular para o conteúdo principal
Ranking Invest

ALBO - Albireo Pharma, Inc.

Segmento: HealthcareAlbireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 197.52 Mi
Último Balanço Atualizado: 3T2022

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 100.07 Mi

Dívida Líquida

-$ 222.48 Mi

L4T

-$ 137.38 Mi

MM4T

-401.97%

Indicadores Básicos

ROE

-137.28%

Índices de Previsibilidade

Receita Líquida

G13.55

Lucro

B0.23

Margem

E1.83

Índices de Tendência

Receita Líquida

B9.47

Lucro

G-8.65

Margem

B7.42

Índices de Endividamento

DIV/PAT

-2.22

DIV/L4T

1.62

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.